Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
About this study
This multicenter, prospective and retrospective observational study aims to evaluate the use and efficacy of new drugs or their combinations in real-life in a population of adult AML patients.
- Condition
- Acute Myeloid Leukemia, AML, Adult, Acute Myeloid Leukemia, Adult
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 12
- Minimum age: 18 years
- Study condition: Acute Myeloid Leukemia, AML, Adult, Acute Myeloid Leukemia, Adult
- Aged 18 years or older
- AML diagnosis according to the ELN guidelines, excluding M3
- Signed Informed consent, if applicable
- Treatment initiation with novel drugs in monotherapy or combination, in accordance with the AIFA authorizations, from the AIFA registration up to 31.12.2027 with particular attention to:
- patients affected by FLT3-mutated AML treated with gilteritinib.
- patients affected by IDH-mutated AML treated with IDH inhibitors.
- patients affected by AML in maintenance therapy with oral azacytidine.
- patients affected by AML treated with glasdegib.
- patients affected by AML treated with gemtuzumab ozogamicin.
- other novel drugs or combination for the treatment of AML approved during the study period.
Exclusion 1
- Patients included in interventional clinical trials.
Where
2 sites, 2 recruiting
Ematologia Ente Ecclesiastico Casa Sollievo Della Sofferenza
San Giovanni Rotondo, Italy
UOC Ematologia AOU di SASSARI
Sassari, Italy
Contact
-
Paola Fazi
0670390528 p.fazi@gimema.it
-
Enrico Crea
0670390514 e.crea@gimema.it
Potential match only. Final eligibility is determined by the study team.